Ultragenyx Pharmaceutical RARE Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -83.8%+3.3pp | -79.5%+16.2pp | -86.4%+16.1pp | -82.9%+31.2pp | -87%+44.1pp | |
| Net margin | -90.9%+2.2pp | -85.5%+16.1pp | -92%+15.1pp | -87.4%+34.3pp | -93.1%+45.7pp | |
| Efficiency | ||||||
| Asset turnover | 0.5×+0.1× | 0.4×+0.1× | 0.5×+0.1× | 0.4×+0.1× | 0.5×+0.1× | |
| Liquidity | ||||||
| Current ratio | 2×-0.4× | 2.5×+0.1× | 1.9×-0.9× | 2.5×-1.1× | 2.4×0.0× | |
| Per Share | ||||||
| Book value per share | -$2.35-257% | -$0.81-129% | $0.09-97.5% | $1.54-69.2% | $1.50-10.1% | |
| Valuation | ||||||
| Market capitalization | $2.06B-39.4% | $2.22B-42.9% | $2.9B-39.7% | $3.51B+1.4% | $3.4B-13.6% | |
| Price / sales | 3.1×-2.7× | 3.3×-3.6× | 4.6×-4.6× | 5.8×-1.4× | 5.8×-3.1× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Ultragenyx Pharmaceutical's profit margins?
- Ultragenyx Pharmaceutical (RARE) runs a 97.2% gross margin and a -83.8% operating margin, with a -90.9% net margin.
- Where do Ultragenyx Pharmaceutical's ratios come from?
- Every ratio is computed from Ultragenyx Pharmaceutical's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
